文献速递认知障碍与痴呆

绝经后激素治疗与阿尔茨海默病:一项前瞻性队列研究

Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study.
PubMed 文献 · Neurology · 2017-02-15

该研究基于Kuopio骨质疏松风险因素与预防队列20年随访数据,纳入8195名47-56岁女性(227例新发AD),评估绝经后激素治疗与AD风险的关联。登记或自报的雌激素使用与AD风险无关,但长期自报HT与AD风险降低相关。结果未提供HT对AD或痴呆有强保护作用的证据。

要点

  • 登记或自报雌激素使用与AD风险无关(HR 0.92/0.99)
  • 长期自报绝经后HT与AD风险降低相关(HR 0.53)
  • 结果不支持HT对AD或痴呆有强保护作用

核心结论

  • 结果未提供绝经后HT使用与AD或痴呆之间存在强保护关联的证据,尽管长期自报HT使用者AD风险降低。

研究设计与样本

  • 基于Kuopio骨质疏松风险因素与预防研究队列的20年前瞻性随访,纳入8195名47-56岁女性,其中227例新发AD。

主要发现

  • 登记或自报绝经后雌激素使用与AD风险无关(HR/95%CI分别为0.92/0.68-1.2和0.99/0.75-1.3)。
  • 长期自报绝经后HT与AD风险降低相关(HR/95%CI 0.53/0.31-0.91)。
  • 以医院出院登记中任何痴呆诊断作为结局时获得类似结果。

关键数值与推荐

  • 可能AD病例基于DSM-IV和NINCDS-ADRDA标准,从特殊报销登记(1999-2009)中识别。

临床怎么用

  • 不应仅基于本研究结果将绝经后HT用于预防AD或痴呆,长期自报HT的关联需进一步验证。

局限性

  • 长期HT使用依赖自报数据,可能存在回忆偏倚;激素处方登记信息仅自1995年起可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore the association between postmenopausal hormone therapy (HT) and Alzheimer disease (AD). METHODS: Twenty-year follow-up data from the Kuopio Osteoporosis Risk Factor and Prevention study cohort were used. Self-administered questionnaires were sent to all women aged 47-56 years, residing in Kuopio Province starting in 1989 until 2009, every 5th year. Register-based information on HT prescriptions was available since 1995. Probable AD cases, based on DSM-IV and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria, were identified from the special reimbursement register (1999-2009). The study population included 8,195 women (227 cases of incident AD). RESULTS: Postmenopausal estrogen use was not associated with AD risk in register-based or self-reported data (hazard ratio/95% confidence interval 0.92/0.68-1.2, 0.99/0.75-1.3, respectively). Long-term self-reported postmenopausal HT was associated with reduced AD risk (0.53/0.31-0.91). Similar results were obtained with any dementia diagnosis in the hospital discharge register as an outcome. CONCLUSIONS: Our results do not provide strong evidence for a protective association between postmenopausal HT use and AD or dementia, although we observed a reduced AD risk among those with long-term self-reported HT use.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Imtiaz B, Tuppurainen M, Rikkonen T, et al. Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study. Neurology. 2017. PMID: 28202700. doi:10.1212/WNL.0000000000003696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。